PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

U.S. Senate panel to debate wave of corporate tax-avoidance deals

Mon, 21st Jul 2014 23:05

By Kevin Drawbaugh

WASHINGTON, July 21 (Reuters) - As more U.S. corporations dodeals to cut taxes by shifting their tax domiciles overseas, theSenate Finance Committee will hold a hearing on Tuesday focusedon these transactions known as inversions.

Nine such deals have been agreed to this year by companiesranging from banana distributor Chiquita Brands International,Inc to drugmaker AbbVie Inc and more are beingconsidered. The transactions are setting a record pace since thefirst inversion was done 32 years ago.

Witnesses at the Senate Finance Committee's hearing willinclude government officials and academics. Chairman Ron Wyden,a Democrat from Oregon, is expected to call for stand-alonelegislation to respond to the flurry of inversions that hasWashington on edge.

Democrats, searching for campaign issues before November'scongressional elections, have jumped on inversions, and severalof them have offered bills that would curb the deals.

But no new law is likely to result as long as Republicanscontend that inversion rules need to be part of a broaderoverhaul of the tax code, policy analysts said.

The Republican-controlled U.S. House of Representatives willnot act on inversions "unless there's comprehensive tax reform,and that's dead for this year," said Greg Valliere, chiefpolitical strategist at Potomac Research Group in a client noteon Monday.

Inversions are still rare, but they are becoming morecommon. Of the roughly 60 deals done since 1982, more than halfhave come in just the last six years, a Reuters review showed.

An inversion involves a U.S. corporation buying or settingup a smaller company abroad, then shifting its tax home base tothat company's country, which typically has lower tax rates thanin the United States.

Such deals seldom mean a U.S. corporation physically leaveshome. Usually an inversion means that a company will open asmall office abroad, perhaps in England or Ireland, as a newaddress for tax purposes, leaving major operations intact.

But the move can put foreign earnings out of the reach ofthe Internal Revenue Service and make other tax savings possiblethat can boost a multinational company's bottom line.

U.S. Treasury Secretary Jacob Lew urged Congress last weekto take steps quickly to discourage inversions.

In a letter to members of Congress, he said corporationsthat do inversions want to keep U.S. advantages - such as intellectual property protection, research support, financialsecurity and reliable infrastructure - without paying for them.

President Barack Obama's 2015 budget proposed makinginversions harder to do by raising the foreign ownershiprequired. Congressional Democrats have made similar proposals.

Drugstore chain Walgreen Co is weighing a possibleinversion. Drugmaker Pfizer Inc's bid in April to buy UKrival AstraZeneca Plc was structured as an inversion.That deal collapsed, but it drew attention to the issue. (Editing by Jan Paschal)

More News
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.